Triplet Therapy in mHSPC: Patient Selection and Treatment Intensification

SPECIAL REPORT

Genitourinary Cancer

Sustained OS Benefit with Enzalutamide Plus ADT in mHSPC Including Patients with Cardiometabolic Comorbidities

Genitourinary Cancer

Treatment Effect of Perioperative (Neoadjuvant and Adjuvant) Apalutamide plus Androgen-deprivation Therapy Versus Radical Prostatectomy Alone in Patients with High-risk Localized or Locally Advanced Prostate Cancer from the PROTEUS Substudy

Eur Urol

Briganti A, Steuber T, Shore ND, Gleave M, Kretschmer A, Wetherhold L, Efstathiou E, Cahn DJ, Damião R, De La Taille A, Byun SS, Hadaschik BA, Imbroda BH, Soto ÁJ, Merseburger AS, Simone G, Rooney B, Mikerin D, Li Z, Miladinovic B, McCarthy SA, Wildgust M, Mundle SD, Kibel AS, Taplin ME

doi: 10.1016/j.eururo.2026.10.016

Further Publications

Real-world burden of cardiovascular events following immune checkpoint inhibitor therapy: impact on mortality and treatment resumption in 29,503 patients

Lung Cancer

Rigaux C, Arangalage D, Adkins K, Illiano S

doi: 10.1016/j.lungcan.2026.109499

Myeloproliferative Neoplasms (MPNs)

Firstline treatment with ruxolitinib versus best available therapy in patients with polycythemia vera: results from the randomized RuxoBEAT trial

Blood Cancer J

Koschmieder S, Isfort S, Teichmann LL, Schafhausen P, Heidel FH, Crodel C, Hochhaus A, Griesshammer M, Sockel K, Jost PJ, Walther D, Döhner K, Göthert JR, Radsak M, Augustin M, Becker H, Giagounidis A, Schaich M, Klausmann M, von Bubnoff N, Stegelmann F, Kortmann M, Zentis M, Frank J, Hagemeier A, Hellmich M, Brümmendorf TH, German Study Group for Myeloproliferative Neoplasms (GSG-MPN)

doi: 10.1038/s41408-026-01644-2

Lung, Respiratory and Thoracic Cancer

Real-World Treatment Patterns and Clinical Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy and ≥ 2 Subsequent Lines of Therapy in the United States

Adv Ther

Sankar K, Unni S, Eberl M, Le H, Herrmann T, Gorsh B, Tang M, Coerts F, Ahmed S

doi: 10.1007/s12325-025-03408-z

Gastrointestinal Cancer

Treatment landscape from first- to third-line therapy and quality of life data of patients with pancreatic cancer from the prospective German PARAGON (Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer) registry (IKF-PARAGON study)

Int J Cancer

Goetze TO, Al-Batran SE, Liersch R, Scheuer L, Goehler T, Kaiser U, Denzlinger C, Brandl S, Pink D, Uhlig J, Maasberg M, Loose M, Schaaf M, Sookthai D, Zäpf B, Pauligk C, Habibzade T, Hofheinz RD, Koch C, AIO Study Group

doi: 10.1002/ijc.70280

Lymphoma

Comparative effectiveness of chimeric antigen receptor (CAR) T-cell therapy versus historical controls in patients with relapse/refractory aggressive B-cell lymphoma: An indirect treatment comparison in the real-world setting

Br J Haematol

Villeneuve PJA, Mozessohn L, Somé NH, Mercer RE, Masucci L, Kouroukis T, Bredeson C, Aktar S, Guan Q, Prica A, Chen CI, Rodin D, Cheung M, Chaudhry M, Gavura S, McKay C, Wong WWL, Chan KKW

doi: 10.1111/bjh.70632

Multiple Myeloma (MM)

Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-Cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study

Clin Cancer Res

Suvannasankha A, Li M, Omofuma O, Hampp C, Phelan M, Breskin A, Shao P, Roccia T, Mukherjee N, Shrestha A, Lee D, Glass J, Kroog GS, Rodriguez Lorenc K

doi: 10.1158/1078-0432.CCR-25-4068

WCLC 2026